文献速递贫血与红细胞疾病

p27Kip1 调控 γ-珠蛋白生成

p27Kip1 regulates γ-globin production.
PubMed 文献 · Blood · 2026-01-01

该研究通过 CRISPR 激活筛选发现 CDKN1B 编码的 p27Kip1 过表达可在转录水平诱导 γ-珠蛋白表达。机制上 p27Kip1 通过抑制 CDK4/6 诱导胎儿血红蛋白(HbF),且可能不依赖 BCL11A 和 ZBTB7A。口服 CDK4/6 抑制剂帕博西尼在镰状细胞病小鼠模型中显著增加 HbF,羟基脲的 HbF 诱导作用可能部分由 CDK4/6 抑制介导;作者认为单用或双用 CDK4/6 抑制剂可能对镰状细胞病和 β-地中海贫血有治疗益处。

要点

  • CDKN1B 编码的 p27Kip1 过表达可在转录水平诱导 γ-珠蛋白表达
  • p27Kip1 通过抑制 CDK4/6 诱导 HbF,可能不依赖 BCL11A 和 ZBTB7A
  • 帕博西尼在镰状细胞病小鼠模型中显著增加 HbF,耐受良好

核心结论

  • 研究确立 CDK4/6 活性与 γ-珠蛋白生成之间的因果关系。
  • 作者认为单用或双用 CDK4/6 抑制剂可能对镰状细胞病和 β-地中海贫血有治疗益处。

研究设计与样本

  • 基础研究:用 CRISPR 激活筛选所有细胞周期蛋白依赖性激酶抑制剂(CDKI)诱导 HbF 的能力。
  • 使用 CDKN1B 突变体、药理学抑制和遗传还原 CDK4/6、遗传拯救实验及镰状细胞病小鼠模型。

主要发现

  • 慢周期红系细胞 γ-珠蛋白表达增加。
  • 过表达 CDKN1B(而非其他 CDKI)在转录水平诱导 γ-珠蛋白表达。
  • p27Kip1 诱导 γ-珠蛋白主要依赖其细胞周期功能相关结构域。
  • 药理学抑制和遗传还原 CDK4/6 均导致 HbF 增加。
  • p27Kip1 通过抑制 CDK4/6 诱导 HbF,机制可能不依赖 BCL11A 和 ZBTB7A。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell disease (SCD) and β-thalassemia are devastating genetic disorders resulting from defects in the β-globin subunit of adult hemoglobin. Both disorders are ameliorated by the induction of γ-globin, a component of fetal hemoglobin (HbF). Therefore, the development of safe, effective, and widely available inducers of HbF is needed. Here, we discovered that slow cycling erythroid cells exhibit increased γ-globin expression. To understand the molecular basis of this, we screened all cyclin-dependent kinase inhibitors (CDKIs) for their ability to induce HbF using CRISPR activation. We found that overexpression of CDKN1B, which encodes p27Kip1 (but not overexpression of other CDKIs), induces γ-globin expression at the transcriptional level. CDKN1B mutants expressing proteins unable to bind/inhibit CDKs and/or cyclins revealed that γ-globin induction by p27Kip1 depends largely on the domains involved in its cell cycle function. Pharmacological inhibition and genetic reduction of CDK4/6 also result in increased HbF. In genetic rescue experiments, we show that p27Kip1 induces HbF by inhibiting CDK4/6, through a mechanism that is likely BCL11A and ZBTB7A independent. Furthermore, palbociclib, an oral CDK4/6 inhibitor, significantly increases HbF in a murine SCD model at doses that are well tolerated. Moreover, we show that HbF induction by hydroxyurea, a drug currently in use to treat SCD, may be mediated in part by CDK4/6 inhibition. Overall, our findings establish a causal relationship between CDK4/6 activity and γ-globin production and suggest that single or dual CDK4/6 inhibitors might be therapeutically beneficial for SCD and β-thalassemia.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Balbin-Cuesta G, Drysdale C, Kerpet C, et al. p27Kip1 regulates γ-globin production. Blood. 2026. PMID: 41411145. doi:10.1182/blood.2025028895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。